GlassScriptPhysician profile
Susan E Thorsen
NPI 1154646735
$914.70
in general payments reported to CMS, 2019-2025
24 companies · $498 in 2025
The $498 reported for 2025 was more than what a typical Adult Health (Nurse Practitioner) provider received nationally (typical 2025 total: $182).
See the full distribution for Adult Health (Nurse Practitioner)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $35.99 · 2022: $126 · 2023: $89.06 · 2024: $165 · 2025: $498.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $753.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $753.01 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genzyme Corporation | $100.98 | 2025 | |
| Abbvie INC. | $90.43 | 2023-2025 | |
| Emd Serono, INC. | $74.41 | 2025 | |
| Taiho Oncology, INC. | $65.66 | 2024-2025 | |
| Seagen INC. | $51.73 | 2021-2023 | Tukysa, Padcev |
| Pfizer INC. | $48.86 | 2024-2025 | |
| E.R. Squibb & Sons, L.L.C. | $44.14 | 2025 | Opdivo |
| Csl Behring | $43.05 | 2022-2025 | Idelvion, Afstyla |
| Celgene Corporation | $42.86 | 2024 | Opdualag |
| Octapharma USA, INC. | $41.56 | 2024-2025 | Octagam Immune Globulin (Human) |
| Astellas Pharma US INC | $40.93 | 2022-2025 | Padcev |
| Daiichi Sankyo INC. | $40.07 | 2021-2022 | |
| Stemline Therapeutics INC. | $28.80 | 2025 | Orserdu |
| Genmab U.S., INC. | $26.15 | 2024 | Epkinly |
| Tempus Ai, INC | $24.53 | 2025 | Xt Cdx |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Takeda Pharmaceuticals U.S.A., INC. | $22.33 | 2025 | Fruzaqla |
| Karyopharm Therapeutics INC. | $19.35 | 2024 | Xpovio |
| Eusa Pharma (US) LLC | $17.28 | 2022 | |
| Array Biopharma INC | $17.15 | 2023 | Mektovi, Braftovi, Lorbrena |
| Janssen Biotech, INC. | $16.67 | 2022 | |
| Pharmaessentia USA Corporation | $15.52 | 2022 | |
| Incyte Corporation | $15.03 | 2025 | Jakafi |
| Ge Healthcare | $13.62 | 2022 | |
| Genentech USA, INC. | $13.59 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Susan E Thorsen listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.